Organization (Hospital)
Hospital Central Dr. Ignacio Morones Prieto
ClinicalTrials.gov lists Hospital Central Dr. Ignacio Morones Prieto as lead sponsor of 11 trials. It has 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Hospital Central Dr. Ignacio Morones Prieto: 11 lead-sponsored trials and 1 legal-entity registration.
Disease areas (46)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hyperpigmentation | 6 |
| Melanosis | 5 |
| Amnesia | 2 |
| Insulin Resistance | 2 |
| Memory Disorders | 2 |
Showing 5 of 46 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2023 | 2 |
| 2022 | 2 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 4 |
| 2017 | 2 |
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 2 |
| 2013 | 2 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: none of the 11 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Poractant Alfa | 1 |
| Budesonide | 1 |
| INSULIN GLARGINE | 2 |
| ATORVASTATIN | 1 |
| Colchicine | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| not enough data | 0 of 1 on time (n=1) |
Journals published in (91)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Hernia : the journal of hernias and abdominal wall surgery | 6 |
| American journal of respiratory and critical care medicine | 2 |
| Contact dermatitis | 2 |
| Experimental dermatology | 2 |
| JACC. Heart failure | 2 |
Showing 5 of 91 journals.
Organization relationships (14)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Juan Pablo Castanedo-Cazares | Co sponsors trial with | 2 |
| Hospital Angeles Lomas | Co sponsors trial with | 1 |
| Instituto Nacional de Cancerologia de Mexico | Co sponsors trial with | 1 |
| Hospital Aranda de La Parra (Leon Guanajuato) | Co sponsors trial with | 1 |
| Hospital Central Militar | Co sponsors trial with | 1 |
Showing 5 of 14 relationships.
Latest dated events (30)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2023-12-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2022-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2022-01-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2020-08-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 30 events.
Biomarker capability evidence (48)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ERVK-10 | Trial collaborator | Named in trial exclusion criteria |
| ERVK-10 | Trial collaborator | Named in trial exclusion criteria |
| ERVK-18 | Trial collaborator | Named in trial exclusion criteria |
| ERVK-18 | Trial collaborator | Named in trial exclusion criteria |
| ERVK-19 | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 48 evidence rows.
Biomarkers this organization publishes on (22)
Shown in this order: most publications first.
Showing 5 of 22 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.